Alamar Biosciences
ALMR
87 hedge funds and large institutions have $664M invested in Alamar Biosciences in 2026 Q2 according to their latest regulatory filings, with 87 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
35.38% more ownership
Funds ownership: 0% → 35.38% (+35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
+$95.7M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$56.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$49.8M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31.1M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$24.5M |
Top Sellers
ALMR Hedge Fund Activity: Q2 2026 in Review
87 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Alamar Biosciences (ALMR) for Q2 2026, worth a combined $664M.
Buyers outnumbered sellers: 87 funds opened new ALMR positions and 0 closed out — a net gain of 87 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sands Capital Ventures, opening a new position worth an estimated $95.7M.
- 87 institutional investors held Alamar Biosciences (ALMR) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $664M of Alamar Biosciences stock for Q2 2026.
- 87 funds opened new Alamar Biosciences positions in Q2 2026 and 0 closed out, a net change of +87 holders.
- The largest Alamar Biosciences buyer in Q2 2026 was Sands Capital Ventures, an estimated $95.7M added.
Based on aggregated 13F filings for Q2 2026.